과제정보
연구 과제 주관 기관 : Ministry for Health and Welfare
참고문헌
- Li C, Yang CW. The pathogenesis and treatment of chronic allograft nephropathy. Nat Rev Nephrol 2009;5:513-519.
- Kasiske BL, Snyder JJ, Gilbertson DT, Wang C. Cancer after kidney transplantation in the United States. Am J Transplant 2004;4:905-913. https://doi.org/10.1111/j.1600-6143.2004.00450.x
- Vincenti F, Friman S, Scheuermann E, et al. Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. Am J Transplant 2007;7:1506-1514. https://doi.org/10.1111/j.1600-6143.2007.01749.x
- Stallone G, Schena A, Infante B, et al. Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N Engl J Med 2005;352:1317-1323. https://doi.org/10.1056/NEJMoa042831
- Saemann MD, Haidinger M, Hecking M, Horl WH, Weichhart T. The multifunctional role of mTOR in innate immunity: implications for transplant immunity. Am J Transplant 2009;9:2655-2661. https://doi.org/10.1111/j.1600-6143.2009.02832.x
- Zhao T, Yang C, Qiu Y, et al. Comparison of regulatory T cells and FoxP3-positive T-cell subsets in the peripheral blood of renal transplant recipients with sirolimus versus cyclosporine: a preliminary study. Transplant Proc 2013;45:148-152. https://doi.org/10.1016/j.transproceed.2012.06.067
- Stallone G, Infante B, Schena A, et al. Rapamycin for treatment of chronic allograft nephropathy in renal transplant patients. J Am Soc Nephrol 2005;16:3755-3762. https://doi.org/10.1681/ASN.2005060635
- Schena FP, Pascoe MD, Alberu J, et al. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation 2009;87:233-242. https://doi.org/10.1097/TP.0b013e3181927a41
- Weir MR, Mulgaonkar S, Chan L, et al. Mycophenolate mofetil-based immunosuppression with sirolimus in renal transplantation: a randomized, controlled Spare-the-Nephron trial. Kidney Int 2011;79:897-907. https://doi.org/10.1038/ki.2010.492
- Guba M, Pratschke J, Hugo C, et al. Early conversion to a sirolimus-based, calcineurin-inhibitor-free immunosuppression in the SMART trial: observational results at 24 and 36months after transplantation. Transpl Int 2012;25:416-423. https://doi.org/10.1111/j.1432-2277.2012.01432.x
- Soleimani AR, Kamkar I, Nikoueinejad H, Moraweji AR. Comparison of cyclosporine and sirolimus effects on serum creatinine level over five years after kidney transplantation. Transplant Proc 2013;45:1644-1647. https://doi.org/10.1016/j.transproceed.2013.01.060
- Diekmann F, Campistol JM. Conversion from calcineurin inhibitors to sirolimus in chronic allograft nephropathy: benefits and risks. Nephrol Dial Transplant 2006;21:562-568. https://doi.org/10.1093/ndt/gfi336
- Alvarez-Lara MA, Carracedo J, Ramirez R, et al. The imbalance in the ratio of Th1 and Th2 helper lymphocytes in uraemia is mediated by an increased apoptosis of Th1 subset. Nephrol Dial Transplant 2004;19:3084-3090. https://doi.org/10.1093/ndt/gfh382
- Lebranchu Y, Thierry A, Toupance O, et al. Efficacy on renal function of early conversion from cyclosporine to sirolimus 3 months after renal transplantation: concept study. Am J Transplant 2009;9:1115-1123. https://doi.org/10.1111/j.1600-6143.2009.02615.x
- Guba M, Pratschke J, Hugo C, et al. Renal function, efficacy, and safety of sirolimus and mycophenolate mofetil after short-term calcineurin inhibitor-based quadruple therapy in de novo renal transplant patients: one-year analysis of a randomized multicenter trial. Transplantation 2010;90:175-183.
- Li Y, Shi Y, Huang Z, et al. CNI induced Th17/Treg imbalance and susceptibility to renal dysfunction in renal transplantation. Int Immunopharmacol 2011;11:2033-2038. https://doi.org/10.1016/j.intimp.2011.08.015
- Chung BH, Kim KW, Kim BM, et al. Dysregulation of Th17 cells during the early post-transplant period in patients under calcineurin inhibitor based immunosuppression. PLoS One 2012;7:e42011. https://doi.org/10.1371/journal.pone.0042011
- Kim KW, Chung BH, Kim BM, Cho ML, Yang CW. The effect of mammalian target of rapamycin inhibition on T helper type 17 and regulatory T cell differentiation in vitro and in vivo in kidney transplant recipients. Immunology 2015;144:68-78. https://doi.org/10.1111/imm.12351
- Yap M, Boeffard F, Clave E, et al. Expansion of highly differentiated cytotoxic terminally differentiated effector memory CD8+ T cells in a subset of clinically stable kid-ney transplant recipients: a potential marker for late graft dysfunction. J Am Soc Nephrol 2014;25:1856-1868. https://doi.org/10.1681/ASN.2013080848
- Pallet N, Legendre C. Adverse events associated with mTOR inhibitors. Expert Opin Drug Saf 2013;12:177-186. https://doi.org/10.1517/14740338.2013.752814
- Chuang P, Langone AJ. Clobetasol ameliorates aphthous ulceration in renal transplant patients on sirolimus. Am J Transplant 2007;7:714-717. https://doi.org/10.1111/j.1600-6143.2006.01678.x
피인용 문헌
- Treatment of Lymphatic Malformations with the mTOR Inhibitor Sirolimus: A Systematic Review vol.16, pp.4, 2016, https://doi.org/10.1089/lrb.2017.0062
- Regulatory B cells and advances in transplantation vol.105, pp.4, 2019, https://doi.org/10.1002/jlb.5ru0518-199r